IMRX vs. AVTE

In the year-to-date period, IMRX achieves a -15.45% return, which is significantly lower than AVTE's -7.55% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Immuneering Corporation (IMRX) and Aerovate Therapeutics, Inc. (AVTE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current IMRX Sharpe Ratio is -0.52, which is higher than the AVTE Sharpe Ratio of -0.75. The chart below compares the historical Sharpe Ratios of IMRX and AVTE, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither IMRX nor AVTE has paid dividends to shareholders.

The maximum IMRX drawdown since its inception was -96.86%, roughly equal to the maximum AVTE drawdown of -95.41%. Use the drawdown chart below to compare losses from any high point for IMRX and AVTE. For additional features, visit the drawdowns tool.

Immuneering Corporation (IMRX) has a higher volatility of 15.20% compared to Aerovate Therapeutics, Inc. (AVTE) at 10.79%. This indicates that IMRX's price experiences larger fluctuations and is considered to be riskier than AVTE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Immuneering Corporation and Aerovate Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.